Kuno, Masashi <br/><br/>
Rho-kinase inhibitors decrease TGF-beta-stimulated VEGF synthesis through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts.  [electronic resource] 

 -  Biochemical pharmacology  Jan 2009 
 - 196-203 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2968 
<br/><br/><label>Standard No.: </label>10.1016/j.bcp.2008.10.014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine--analogs & derivatives<br/>3T3 Cells<br/>Animals<br/>Animals, Newborn<br/>Enzyme Inhibitors--pharmacology<br/>JNK Mitogen-Activated Protein Kinases--metabolism<br/>Mice<br/>Myosin-Light-Chain Kinase--metabolism<br/>Myosin-Light-Chain Phosphatase<br/>Osteoblasts--drug effects<br/>Phosphorylation<br/>Protein Kinase Inhibitors--pharmacology<br/>Skull--cytology<br/>Transforming Growth Factor beta--pharmacology<br/>Vascular Endothelial Growth Factor A--biosynthesis<br/>p38 Mitogen-Activated Protein Kinases--metabolism<br/>rho-Associated Kinases--antagonists & inhibitors